Long-term safety of vedolizumab for inflammatory bowel disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety of vedolizumab for inflammatory bowel disease

Published:2020-09-02 Issue:8 Volume:52 Page:1353-1365
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment. Pharmacol. Ther.

Author:

Loftus Edward V.¹^ORCID,Feagan Brian G.²^ORCID,Panaccione Remo³^ORCID,Colombel Jean-Frédéric⁴^ORCID,Sandborn William J.⁵^ORCID,Sands Bruce E.⁴^ORCID,Danese Silvio⁶^ORCID,D’Haens Geert⁷^ORCID,Rubin David T.⁸^ORCID,Shafran Ira⁹,Parfionovas Andrejus¹⁰,Rogers Raquel¹⁰,Lirio Richard A.¹⁰^ORCID,Vermeire Séverine¹¹^ORCID

Affiliation:

1. Rochester MN USA

2. London ON Canada

3. Calgary AB Canada

4. New York NY USA

5. San Diego CA USA

6. Milan Italy

7. Amsterdam The Netherlands

8. Chicago IL USA

9. Winter Park FL USA

10. Cambridge MA USA

11. Leuven Belgium

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.16060/fullpdf

Reference22 articles.

1. Crohn's disease;Torres;Lancet,2017

2. Ulcerative colitis;Ungaro;Lancet,2017

3. ENTYVIO (vedolizumab) prescribing information

4. Vedolizumab [summary of product characteristics] Taastrup, Denmark Takeda Pharma A/S

5. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med,2013

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab;Biomedicines;2024-01-11

2. Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials;Expert Opinion on Emerging Drugs;2024-01-09

3. Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels;Journal of Clinical Medicine;2023-12-27

4. Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions;Clinical and Experimental Gastroenterology;2023-12

5. Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease;Mucosal Immunology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3